Abstract. The Ets proteins are a family of transcription factors characterized by an evolutionarily conserved DNA binding domain that controls key cellular processes. Prostate-derived Ets transcription factor (PDEF), a member of the Ets family, is reported to be present in tissues with high epithelial content, notably breast and prostate. However, the role of PDEF in cancer development is not fully understood. To gain insight into the molecular mechanisms associated with prostate cancer progression, we employed iTRAQ labeling followed by mass spectrometric (MS) analysis to identify candidate proteins that are differentially expressed in prostate cancer cells with or without PDEF. To this end, we overexpressed PDEF in PC3 human prostate cells using a tetracycline inducible system (Tet-On). Many differentially expressed proteins which play important roles in various cellular and biological processes were identified. Among them, stathmin (STMN), which is a microtubule (MT)-destabilizing protein, was found to be downregulated in multiple analyses. We demonstrated that re-expression of STMN reversed the antitumor properties of PDEF in PDEF-overexpressing PC3 cells. Using in vitro functional assays, we showed that STMN overexpression counteracted PDEF's effects against cell proliferation, colony formation and tumor migration. Similar results were further confirmed with the prostate cancer cell line CWR22rv1. In conclusion, many differentially expressed proteins were identified and STMN was found to be downregulated by PDEF.
Introduction
Prostate cancer is the most common cancer diagnosed among men and the second leading cause of death in American men, behind only lung cancer. The American Cancer Society (ACS) estimates about 1 man in 36 will die of prostate cancer (1) . Although screening for prostate cancer, based on prostate specific antigen (PSA) has revolutionized early detection and diagnosis of the disease, the challenge that clinicians face are to determine which patients progress to aggressive disease (2, 3) . In order to determine the possibility of disease progression and ability to manage patient outcomes, it is necessary to better understand the molecular processes underlying the disease development and progression. Gene regulation is an important process in maintaining the integrity of cells for their proper growth and survival. Improper regulation of genes can lead to various diseases like cancer. The Ets family of transcription factors has been long investigated for their role in genetic loss of cellular homeostasis which results in development of various cancers. So far, 25 human and 26 murine Ets family members have been reported (4) . Ets family of proteins share a conserved winged helix-turn-helix DNA binding domain called the Ets domain which recognizes unique DNA sequences containing GGAA/T. Eleven Ets proteins have a pointed (PNT) domain, important in protein-protein association. Ets proteins control many important cellular processes, including proliferation, differentiation, angiogenesis and apoptosis (4) (5) (6) (7) (8) (9) (10) (11) . Prostate-derived Ets transcription factor (PDEF), a member of the Ets family has been widely investigated for its role in cancer development and progression. Originally identified from the prostate epithelium, PDEF controls the expression of PSA, a specific marker for prostate cancer (12) . Immunohistochemical analysis has shown the presence of PDEF in all high-epithelial content tissues such as breast and prostate (13, 14) . Early reports showed that PDEF was a tumor promoter (13, 14) . However, recent studies support its role as a tumor suppressor based on differing model systems and varying experimental conditions (14, (15) (16) (17) (18) .
In order to gain insight into the function of PDEF, in the present study we used isobaric tags for relative and absolute quantitation (iTRAQ)-labeling coupled with mass spectrometry (MS) to identify differentially expressed proteins upon PDEF induction using a Tet-On system in prostate cancer cells (19) . This study is the first to report the use of iTRAQ labeling MS to identify differentially expressed proteins upon PDEF induction and validate the results with in vitro functional assays (20, 21) . iTRAQ coupled with MS has significant advantages over other methods due to its capability of multiplexing samples in one experimental setup (20, 22) . Another positive aspect includes unbiased peptide labeling, since iTRAQ tags label lysine side groups and all free amino-terminal groups of the peptides present in the sample (23) . Keeping this background in mind, we thought it would be worth exploring the PDEF proteome using iTRAQ labeling with MS and validate the results with in vitro assays to study the role of PDEF in prostate cancer progression. To date only one study has been done in MDA-MB-231 human breast cancer cells analyzing interacting protein complexes to overexpressed PDEF (24) . Cho et al used adenoviral-mediated gene delivery system to overexpress PDEF and LC-MS/MS analysis to identify protein complexes. They identified 121 proteins and their findings suggested PDEF may be regulated by ERBB2 or EGFR-activated signaling pathways in breast cancer (24) . No proteomics research work has been done coupled with in vitro functional assays with PDEF in prostate cells. Our research is the first to utilize iTRAQ labeling to identify differentially expressed proteins upon PDEF induction in prostate cancer cells and verify the results with in vitro assays to study the role of PDEF. We identified 115 proteins, of which 35 were upregulated and 80 were downregulated in the two sets of prostate cancer cells. Stathmin (STMN), a microtubule (MT)-destabilizing protein, was found downregulated mulitple times in the presence of PDEF in the analyzed sample sets and therefore took our attention. Further, the in vitro functional assays such as proliferation, migration and colony formation used to verify the results confirmed correlation of PDEF with the downregulation of STMN in PDEF overexpressing prostate cancer cells (PC3 and CWR22rv1).
Materials and methods

Chemicals and reagents.
The following primary antibodies were used: hPDEF rabbit polyclonal antibody (PDEF N-terminal construct obtained from the Laboratory of Dennis K. Watson from the Medical University of South Carolina antibody made by Proteintech, IL), STMN antibody (EMD Chemicals, Inc.) and anti-actin antibody (Santa Cruz Biotechnology, Inc.); secondary antibodies used for western blots were: horseradish peroxidaseconjugated anti-goat (Roche Applied Science), anti-mouse (Bio-Rad) and anti-rabbit Santa Cruz Biotechnology, Inc.); and G418 Sulfate/Neomycin (Invitrogen, Inc.) and Puromycin (Sigma, Inc.) were used for selection of stable clones.
Cell culture. The human prostate cancer cell lines PC3 and CWR22rv1 and stable transfectants (ATCC) were maintained in RPMI-1640 (Invitrogen, Inc.) supplemented with 5% fetal bovine serum (FBS; Invitrogen, Inc.) and antibiotic liquid (penicillin and streptomycin; Invitrogen, Inc.) at 37˚C under 5% CO 2 .
A Tet-On prostate cancer cell line was used (19) and PDEF expression was routinely induced by using doxycycline (DOX) (RPI, Inc.) at a concentration of 1 µg for 24 h in PC3 cells. This system can induce activation of target gene (i.e., PDEF in our study) in a stringent, reversible, specific manner to study underlying biological and pathological processes (25) .
RT-PCR analysis. Total cellular RNA was isolated from cell lines using the TRIzol Reagent (Invitrogen, Inc.) according to the manufacturer's instructions. A two-step RT-PCR was used to analyze mRNA expression of STMN and GAPDH genes. A cDNA was created using oligo(dT) primer and the Moloney murine leukemia virus reverse transcriptase enzyme according to manufacturer's instructions (Invitrogen, Inc.). Standard PCR techniques were then conducted with gene-specific primers. The primer set used for PDEF amplification was as follows: forward primer 5'-GGT GAA AGA ACT GGA GAA GCG-3' and reverse primer 5'-GTG CTT ATC CTT CTC TCG C-3'. iTRAQ protein sample preparation. Protein extraction was performed according to Applied Biosystems (now AB-SCIEX) protocol available from their website (http://www.absciex. com/). Briefly, adherent cells were detached using trypsin then washed twice with phosphate-buffered saline (PBS). Pelleted cells were homogenized in radioimmunoprecipitation assay buffer (RIPA) buffer containing a cocktail of HALT protease inhibitors (Thermo Scientific, Inc.). The cells were vortexed and kept on ice for 30 min and then centrifuged at 10000 x g for 20 min at 40˚C. The protein concentration of the supernatants was determined by the bicinchoninic acid (BCA) protein assay kit (Thermo Scientific, Inc.) and stored in aliquots at -20˚C until use.
Isobaric labeling. One hundred micrograms of protein from the [PC3 tetracycline (Tet-On) control-uninduced and PC3 Tet-On PDEF-induced] cells were subjected to trichloroacetic acid (TCA) precipitation followed by several washes in acetone to remove Tris and detergents. The pellet was reconstituted by resuspending into 20 µl of 8 M urea/500 mM triethylammonium bicarbonate (TEAB). Subsequently, the resuspended proteins were reduced, alkylated with iodoacetamide and digested with trypsin (Promega, Madison, WI) according to manufacturer's protocol (AB SCIEX, Framingham, MA, USA). Samples were iTRAQ labeled as follows: PC3 Tet-On controluninduced was labeled with the 114 reagent and PC3 Tet-On PDEF-induced was labeled with the 117 reagent, samples were pooled and a preparative desalting was done using an mRP C18 reverse phase column (Agilent Technologies). iTRAQ labeling experiment was repeated for reproducibility. Peptide fractions were collected (~15 ml each) and concentrated in a vacuum concentrator to ~0.3 ml prior to fractionation.
OFFGEL fractionation. Peptides were separated using an Agilent 3100 OFFGEL Fractionator (Agilent, G3100AA). The OFFGEL isoelectric fractionation was run with commercially available IPG Dry strips pI 3-10 (GE Healthcare) in dilute glycerol only (no amphophiles added) with the standard 12-well peptide fractionation program until 20 kVh was accumulated (~24 h), then each of the 12 fractions was either injected directly onto the LTQ (Thermo Fisher) linear ion trap mass spectrometer or fractions were desalted using C18 Porous R2 (Applied Biosystems) prior to loading onto the LTQ (26) .
Mass spectrometric analysis and data processing. Individual OFFGEL fractions were infused separately onto a Thermo Electron Finnigan linear ion trap mass spectrometer (LTQ) operated in positive ion mode via a Dionex U-3000 Ultimate nano LC system running. Peptides were separated on a C18 column (Agilent Zorbax 300SB-C18, 3.5 µm, 75 µm x 150 mm) at a flow rate of 250 nl/min eluted with a linear gradient of 10-60% solution B (95% ACN, 0.1% formic acid) over 80 min. A survey full scan (m/z = 400-2000) and the five most intense ions were selected for a zoom scan to determine the charge state, after which MS/MS was triggered in Pulsed-Q Dissociation mode (PQD) with minimum signal required (1000), isolation width 2.0, normalized collision energy 31.0, activation Q 0.600 and activation time of 0.400. PQD mode is critical in order to visualize the low m/z reporter ions from the iTRAQ reagents used for relative quantitation. Mass spectrometry data were acquired with Xcalibur software version 2.0 SR2. Each resulting RAW file was extracted using Readw.exe (version 4.0.2, Institute for Systems Biology) to produce mzXML files and with DTASuperCharge (University of Southern Denmark) to give MGF files. Individual MGF files were merged using a text editor for searching. Protein identification was performed using a Sorcerer search appliance (SageN) running the SEQUEST algorithm using the IPI Human database v3.50 using iTRAQ (K and N-terminal) as fixed modifications and oxidation of methionine and carbamidomethylation of cysteine as variable modifications using a peptide tolerance of 2.0 Da and fragment tolerance of 0.6 Da. These results were visualized using Scaffold 2.1 (Proteome Software). Proteins were also identified by searching the merged MGF file against Mascot 2.2 search engine (MatrixScience) using the IPI Human database v3.50, using iTRAQ 4-plex quantitation (quantitation methods were modified for carbamidomethylation instead of methylthio). The resulting .DAT file was extracted to generate the .CSV result file for further analysis.
The Mascot search engine returns the relative ratio to 114, so 117/114 <1 corresponds to downregulation and 117/114 >1 corresponds to upregulation. The searches were also run using a decoy database to give us an estimate of false positive rate against the IPI human database. The 114 and 117 ratios were compensated during the analysis.
MTT in vitro cell proliferation assay. Cells were seeded at 1000 cells/well in 96-well dishes and allowed to grow at 37˚C with 5% CO 2 . At each time point MTT [3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide] reagent (5 mg/ml) was added in a volume of 10 µl per well and incubated at 37˚C with 5% CO 2 for 3 h. The media were aspirated and 100 µl of DMSO was added and mixed until a uniform purple color formed. The cell samples were measured using a plate reader at 570 nm. Assays were performed in triplicates.
Soft agar colony formation assay. As described previously (16), 6-well dishes were plated with bottom agar (1.3 ml 1.8% agarose and 0.3 ml of 2X DMEM) for 20-30 min. Cells were mixed with the top agar (0.3 ml 1.8% agarose and 0.7 ml DMEM) at a concentration of 5x10 4 cells per ml and plated in 6-well dishes and allowed to solidify. The cells were grown at 37˚C for 2 weeks, cells stained for 1 h with 0.05% crystal violet and the number of purple colored colonies were tabulated. Three independent experiments (in duplicates) were averaged for graphical representation.
Wound healing migration assay. Cells were seeded in 6-well plates in duplicates so that the cells were 90% confluent the next day. Cells were seeded in RPMI-1640 medium containing 5% FBS overnight. The next day, monolayer of cells was washed with PBS and a wound was created with a pipette tip. Cells were washed again with PBS to remove any leftover cells after the wound was created. The wound was allowed to close in serum-free medium for 24 h. Images were taken at a magnification of x100 and at time points of 0 and 24 h at the same position the wound was created. Cells which migrated towards the wound for closure were counted in duplicate wells and averaged: results represented as percent migrated cells.
Results
Selection criteria of peptides for quantitation of iTRAQ analysis.
In order to obtain reliable analytical measurements, the experiments were repeated more than once. Based on the selection criteria pre-set, all peptides were used for quantitation with: i) a significance threshold p<0.05, ii) require bold red, as per Mascot's search criteria (http://www.matrixscience. com) and iii) minimum 2 peptides/protein. A total of 115 proteins were identified and quantified (≥95% confidence; ≥2 peptides/protein), 35 proteins were upregulated (>1.0) and 80 downregulated (<1.0) in uninduced cells relative to induced PC3 Tet-On cells.
Identification of differentially expressed proteins upon PDEF induction.
To identify proteins differentially expressed upon PDEF induction, PC3 Tet-On system was used as described previously (25) . The western blot analysis of the induced sample (Fig. 1A) showed a 3-fold higher expression of PDEF in comparison to uninduced sample control (Fig. 1B) . After confirming the protein expression, uninduced and induced cells were iTRAQ labeled separately as represented schematically in Fig. 1C . We identified 115 proteins from our analysis of the iTRAQ labeling experiment (Table I ). All 115 proteins fell into the preset selection criteria set by us and only these proteins were used for any further analysis. Of the 115 proteins identified as differentially expressed, 80 proteins were downregulated and 35 proteins were upregulated upon PDEF induction (Table I) . As mascot search returns its ratios relative to 114, therefore all those proteins >1.0 were found upregulated and all the proteins <1.0 were found downregulated upon PDEF induction. Criteria for selection of target protein for further analysis. Our study was based on 3 basic criteria for the selection of target protein for further study in relation to PDEF in the process of prostate cancer progression: i) proteins with the iTRAQ ratio (>1.0 or <1.0), ii) number of times the protein showed up in the analyzed sample sets (>2 times) and iii) role in the prostate cancer process (based on the literature). Based on the above criteria, we first analyzed the differentially expressed proteins with the iTRAQ ratios >1.0 and <1.0. 80 proteins were downregulated with a ratio below 1.0 and 35 were upregulated with a ratio above 1.0 (Table I) . Most of the proteins were found downregulated (<1.0) upon PDEF induction in PC3 prostate cancer cells.
Based on our second selection criteria, 11 out of the 115 proteins showed differential expression three times or more (>3 times) in the analyzed sample sets (Table I ). The proteins were heterogeneous nuclear ribonucleoprotein (HNRNPU), tubulin, heat shock proteins (HSP), peptidyl propyl isomerase, stathmin, actin, tropomyosin (TPM), cortactin (CTTN), ribosomal protein, eukaryotic translation initiation factor (EIF) and histones. In order to further narrow down our search, we decided to exclude those proteins which were associated to any isoforms or were highly similar to the identified proteins. Also proteins that were identified as chains (α or β), types (type 2E and B), subunits such as S21, S10 or proteins that came as forms of the identified protein (such as mitochondrial and cytoplasmic) were all excluded from our study. Based on our exclusion criteria we found only one protein STMN. STMN was found differentially expressed multiple times and was taken into consideration for further analysis.
STMN was found extensively studied in relation to the cancer progression process (27, 28) and in many studies directly linked to prostate cancer (29, 30) . STMN in our study was found downregulated multiple times (0.829, 0.829 and 0.783) as seen in Table I . Keeping all these considerations in mind, we focused our research primarily on the association of STMN and PDEF in the process of prostate cancer progression.
Stathmin, a differentially expressed protein. Stathmin (STMN)
has been extensively studied in cancer progression, specifically in relation to prostate cancer (29, 30) . STMN, also known as p17, p18, p19, 19k, metablastin, oncoprotein 18, LAP18, Op18, is a 19-kDa cytosolic protein. It was the first discovered member of family of MT-destabilizing phosphoproteins (31, 32) . This protein was critically involved in the assembly and disassembly of the mitotic spindle involved in the progression through the cell cycle (29, 33) . Western blot analysis ( Fig. 2A) and mRNA expression level (Fig. 2B ) of PC3 control and hPDEF cell lysates confirmed the downregulation of STMN in PC3 hPDEF cells.
Relevance of STMN to the prostate cancer progression process.
To further evaluate the relevance of STMN and PDEF associ- ation during the process of prostate cancer progression. The proliferative, migratory and colony forming potential of prostate cancer cells were evaluated in PC3 cells as well as CWR22rv1, another prostate cell line. Both PC3 and CWR22rv1 stable transfectants showed a significant change in cells overexpressing hPDEF+STMN in comparison to hPDEF cells alone. PC3 and CWR22rv1 hPDEF cells display a tumor suppressing effect, which is reversed in the presence of STMN. Our previous in vitro and in vivo data prove that PDEF is a tumor suppressor in breast cancer cells. We showed that PDEF-expressing cells block the cell growth rate, and this retardation was reversed when PDEF expression was silenced with PDEF-specific small interfering RNA (16) . Upon STMN expression PDEF overexpressing cells show increased growth potential in an MTT proliferation assay in both PC3 (Fig. 3A) and CWR22rv1 (Fig. 3B) prostate cells. The increase in growth rate was ~2 times more than that of PC3 hPDEF cells, but was lower than the PC3 prostate cancer cells. CWR22rv1 prostate cancer cells also showed similar reversal effect in CWR22rv1 hPDEF+STMN cells but was not as significant as PC3 prostate cancer cells. This difference in both the prostate cancer cell lines could be attributed to the aggressiveness of the cell lines. Soft agar colony formation potential of hPDEF cells in both prostate cancer cell types was significantly increased (PC3, p<0.015; CWR22rv1, p<0.036) in the presence of STMN in hPDEF cells (Fig. 4) . The colonies formed were distinctly larger in the presence of STMN in comparison to all other cell types. This result clearly demonstrates the anchorageindependent growth potential. In the presence of STMN, the colonies formed faster and were significantly larger in both the PC3 and CWR22rv1 hPDEF+STMN cells than in the PC3/ CWR22rv1 hPDEF cells alone. Clearly showing the importance of the association of STMN and PDEF in the cancer progression process, as anchorage-independence is one of the key characteristics of cancer cells. Anchorage-independence helps cancer cells to grow and distribute themselves throughout the body. The migratory potential was significantly increased in the presence of STMN in PC3 (p<0.0055) and CWR222rv1 (p<0.023) cells (Fig.5) . The migratory potential of PC3 hPDEF+STMN cells increased by ~50% in comparison to PC3 hPDEF cells. In CWR22rv1 hPDEF+STMN cells the migratory potential was increased by ~30-35%. STMN in the presence of hPDEF showed a significant change in the key steps of the cancer progression process such as proliferation, colony formation and migration. The above results from the in vitro functional assays clearly demonstrate the change due to the introduction of STMN in hPDEF in PC3/CWR22rv1 cells. It also shows the importance of the association of STMN and PDEF in the cancer progression process. The results from the above described in vitro functional assays have been summarized graphically in Fig. 6 . The data clearly point to the importance of PDEF and STMN association in the process of prostate cancer progression.
Discussion
The Ets family of proteins consists of a large number of evolutionarily conserved transcription factors. Many of Ets factors have been implicated in key steps of the tumor progression process (6, 11) . Extensive studies have been done with Ets family proteins focusing on their biochemical properties and cellular functions (4, 34) . Following the discovery of PDEF in year 2000 (35) , much work has been done to understand the role of PDEF in the process of normal growth and development and in cancer progression. PDEF, a key Ets transcription factor has been studied by various groups involved in the process of tumor progression (17, 36, 37) .
In the present study, we used iTRAQ labeling and proteomic approaches to analyze the differentially expressed proteins in prostate cancer cells upon PDEF induction and confirmed their association using in vitro functional assays. We have not only used a different approach to identify PDEF regulated proteins but also analyzed the effect of PDEF and STMN association on prostate tumor progression. We are the first to use iTRAQ technology to explore the PDEF proteome in cancer cells and verify our results with in vitro assays. We used iTRAQ technology as it has significant advantages over other methods coupled with mass spectrometric analysis. The major advantage of iTRAQ labeling is the capability of multiplexing different samples at the same time to avoid experimental bias. Another positive aspect includes unbiased peptide labeling, as the peptide reactive group is able to bind with all free amino groups to the peptide in the sample (20, 38, 39) .
We identified various proteins as differentially expressed from the analyzed experimental sets. Many of the proteins identified were downregulated upon PDEF induction. STMN was selected as the candidate protein for further analysis based on three set selection criteria. Firstly, STMN was identified with an iTRAQ ratio (<1.0), secondly STMN showed up multiple times (3 times) in all analyzed sample sets and lastly extensive research was done with STMN in prostate cancer, including designing therapeutic targets. Finally one other reason in consideration was the fact that STMN gene reveals multiple transcription factor recognition sequences: two AP-2 sites, five GC boxes and four E2F sites (40, 41) . The presence of multiple transcription factor recognition sequences gives us more confidence of the possibility of a site for PDEF binding on STMN. STMN is overexpressed in many human malignancies including leukemia (42) , lymphoma (43) , neuroblastoma (44); ovarian (45) , prostatic (46) , breast (47, 48) and lung cancer (49) . In many of these cancers, high STMN expression correlates with bad prognosis. It is upregulated in normal proliferating cell lines and also rarely upregulated in non-proliferating cell lines with the exception of neurons (50) . STMN expression is highest when the prostate is undergoing morphogenesis or tumorigenesis and these processes may be regulated through differential phosphorylation (30) . One of key function of STMN is to alter microtubule dynamics based on the need of the cells. STMN plays a role in both the overexpression and inhibition of expression, which could result in mitotic arrest due to microtubule altering effects providing an attractive therapeutic target in cancer therapy (29, 51, 52) .
STMN has been extensively studied in relation to prostate cancer, exerting a profound influence on cell proliferation, differentiation and cell motility. Mistry et al has shown a dramatic dose-dependent growth inhibition in LNCaP prostate cancer cells transduced with anti-STMN adenovirus (53) . STMN has provided an attractive molecule to target for cancer therapies that can disrupt the mitotic apparatus (29) . Research showed that the anti-STMN ribozyme and low non-inhibitory concentrations of Taxol and etoposide had a profound synergistic inhibitory effect on proliferation, clonogenicity and induction of apoptosis. This was found to be very relevant for the treatment of prostate cancer as both Taxol and etoposide are agents that have been used earlier to treat this disease (53) .
Our in vitro functional data showed that STMN was not seen in PC3 hPDEF cells in comparison to control cells with an antibody specific to STMN (Fig. 2A) . PC3 hPDEF cells had a protein expression level 3-fold greater than the PC3 control cells (Fig. 1A and B) . RT-PCR analysis showed that the mRNA expression level of STMN using specific primers was decreased ~1.5-fold in PC3 hPDEF cells in comparison to controls (Fig. 2B) . This result was in consensus with our iTRAQ data that showed decreased expression of STMN upon PDEF induction.
We were able to further analyze the effect of STMN in the presence of PDEF induction by in vitro functional assays. In vitro MTT proliferation assay, anchorage-independent soft agar colony formation and wound healing migration assay clearly showed that PC3 and CWR22rv1 hPDEF cells were able to inhibit proliferation (Fig. 3) , colony formation (Fig. 4) and migration of prostate cancer cells (Fig. 5) . Upon STMN expression in the hPDEF cells, all important steps of the cancer progression process were almost completely reversed back to that of the control (Fig. 6) . STMN expression significantly increased proliferation, colony forming potential and migratory effects of PC3/CWR22rv1 hPDEF cells. Interestingly our data clearly suggested an association of STMN and PDEF with prostate cancer cells. Though we did see an almost complete reversal of prostate cells upon STMN expression, it was not 100% and this difference could be attributed to other PDEFassociated proteins that may play role in the process either along with STMN or alone.
STMN has proven to be an interesting protein that was identified multiple times as downregulated upon PDEF induction. The data obtained from functional assays further confirm the findings and provide new insights into the role of PDEF in regulating the prostate cancer process associated with STMN. PDEF has been studied in our laboratory as a tumor suppressor (16) and with the use of iTRAQ labeling and mass spectrometric analysis techniques we were able to shed light on a possible role of PDEF in prostate cancer cells.
Because of the interesting in vitro functional data that support our iTRAQ-MS research it would be worth studying the in-depth association of STMN with PDEF at a molecular level to better understand the disease process. Validating other identified significantly expressed proteins in the presence or absence of STMN upon PDEF induction could explain why there was not a complete reversal upon STMN expression seen in our in vitro studies.
Compelling evidence from the literature has shown that STMN is a target for anti-cancer therapeutics. Our findings suggest that PDEF may be used to suppress STMN oncogene expression and be used for the development of effective therapeutic strategies for the treatment of prostate cancer. The therapeutic strategies designed can also be used in other cancers.
